HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 2005-0480v1 24/7/1798    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, D. Articles by Shin, C. S. Search for Related Content PubMed PubMed Citation Articles by Kim, D. Articles by Shin, C. S.

TRANSLATIONAL AND CLINICAL RESEARCH

Retrovirus-Mediated Gene Transfer of Receptor Activator of Nuclear Factor-B-Fc Prevents Bone Loss in Ovariectomized Mice

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Key Words. Receptor activator of nuclear factor-B • Receptor activator of nuclear factor-B-Fc • Mesenchymal stem cell • Gene therapy • Osteoporosis • Ovariectomy

Correspondence: Chan Soo Shin, M.D.,Department of Internal Medicine, Seoul National University College of Medicine, 28 Yungun-Dong, Chongno-Gu, Seoul 110-744, Korea. Telephone: +82-2-2072-3734; Fax: +82-2-765-3734; email: csshin{at}snu.ac.kr

Received September 30, 2005; accepted for publication March 16, 2006.
First published online in STEM CELLS EXPRESS   March 23, 2006.


Postmenopausal osteoporosis is characterized by increased bone resorption due to estrogen deficiency. Receptor activator of nuclear factor-B-Fc (RANK-Fc), a fusion protein that specifically blocks receptor activator of nuclear factor ligand binding to RANK, has been known to be efficient and well tolerated in animal models of osteoporosis. Here we show that cell-based gene therapy with RANK-Fc effectively prevented bone loss in ovariectomized (OVX) mice. Thirty-one young adult female C57Bl/6 mice were used, and repeated intraperitoneal injection of mesenchymal stem cells (MSCs) transduced with retrovirus was performed as follows: 1) Sham-operated mice (n = 8); 2) OVX mice treated with phosphate-buffered saline (OVX-PBS; n = 8); 3) OVX mice injected with MSCs transduced with control retrovirus (OVX-green fluorescent protein [GFP]; n = 7); and 4) OVX mice injected with MSCs transduced with RANK-Fc (OVX-RANK-Fc; n = 8). Cellular expression of RANK-Fc was confirmed by Western blot analysis of cell lysates and conditioned medium and also by enzyme-linked immunosorbent assay for the mice serum. Measurement of bone mineral density (BMD) by dual-energy x-ray absorptiometry (PIXImus) revealed that the OVX-RANK-Fc group gained significantly higher BMD than either the OVX-PBS group or OVX-GFP group after 8 weeks. The expression of GFP, which is coexpressed with RANK-Fc, was detected by polymerase chain reaction analysis of DNA isolated from femur and intra-abdominal fat, whereas no GFP signal was identified in liver, brain, heart, lung, or bone marrow aspirates. These suggest that expression of RANK-Fc by genetically modified MSCs may be a feasible option for the prevention of bone loss induced by ovariectomy.

This article has been cited by other articles:

				F. Lamoureux, G. Picarda, J. Rousseau, C. Gourden, S. Battaglia, C. Charrier, B. Pitard, D. Heymann, and F. Redini Therapeutic efficacy of soluble receptor activator of nuclear factor-{kappa}B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma Mol. Cancer Ther., October 1, 2008; 7(10): 3389 - 3398. [Abstract] [Full Text] [PDF]